Yoshitsu Co., Ltd Announces Strategic Cooperation with Tasly Holding Group Co., Ltd

Tokyo, Japan, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Yoshitsu Co., Ltd (“Yoshitsu” or the “Company”) (Nasdaq: TKLF), a retailer and wholesaler of Japanese beauty and health products, as well as sundry products and other products in Hong Kong, mainland China, Japan, North America, and the United Kingdom, today announced that on October 18, 2023, the Company entered into a strategic cooperation agreement (the “Agreement”) with Tasly Holding Group Co., Ltd. (“Tasly”), a Chinese pharmaceutical conglomerate, to cooperate with the investment, research and development, and sales of health products globally. Yoshitsu expects this collaboration with Tasly to help solidify and grow Yoshitsu’s presence in the health product sector.

Yoshitsu and Tasly also plan to assist each other with the registration and approval procedures necessary for health products to be sold in Japan, mainland China, Hong Kong, Macau, and other overseas markets. Yoshitsu and Tasly aim to utilize their respective sales networks and logistics distribution systems to help each other improve their respective supply chain systems and distribution channels in international markets.

Mr. Mei Kanayama, the Principal Executive Officer of Yoshitsu Co., Ltd, commented, “We believe that this alliance with Tasly demonstrates our commitment to grow our presence in the health product sector. Through this partnership, we plan to innovate our offerings in the health product sector. We plan to maintain a long-term partnership with Tasly, which we believe will not only facilitate our investment and finance activities in the health product sector, but may also offer us opportunities to expand our sales and logistics system in both the Japanese market and overseas markets. Moving forward, we expect to continue to seek and foster partnerships that can support our blueprint for business expansion.”

About Tasly Holding Group Co., Ltd.

Tasly Holding Group Co., Ltd., founded in 1994, is a high-tech enterprise group. It focuses on the health industry with biopharmaceuticals development as its core business and biomedical engineering as an auxiliary business. Tasly is also engaged in medical rehabilitation and health maintenance and management services. Tasly ranks among the top 500 manufacturing enterprises in China, the top 500 private enterprises in China, and the top 100 leading enterprises in China's strategic emerging industries, according to China Enterprise Confederation and China Enterprise Entrepreneurs Association. Its core subsidiary enterprise, Tasly Pharmaceutical Group Co., Ltd., was listed on the Shanghai Stock Exchange in 2002. All information about Tasly has been reviewed and approved by Tasly Holding Group Co., Ltd. Additional information is available at https://en.tasly.com/.